YU71604A - Oksa-i tijadijazoli i njihova upotreba kao inhibitora metalo proteinaze - Google Patents
Oksa-i tijadijazoli i njihova upotreba kao inhibitora metalo proteinazeInfo
- Publication number
- YU71604A YU71604A YU71604A YUP71604A YU71604A YU 71604 A YU71604 A YU 71604A YU 71604 A YU71604 A YU 71604A YU P71604 A YUP71604 A YU P71604A YU 71604 A YU71604 A YU 71604A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- thiadiazoles
- oxa
- metalloproteinase inhibitors
- inhibitors
- metalloproteinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Jedinjenja formula (IA ili (IB) što je naznačeno time da W predstavlja HO(C=O)-, HONH(C=O)- ili H(C=O)N(OH)-; X predstavlja -O- ili -S-; i R1, R2, a R3 su kako je definisano u opisu i zathevima, inhibitori matričnih metaloproteinaza, posebno MMP9 i/ili MMP12.[Compounds formula (IA) or (IB), wherein W represents HO(C=O)-, HONH(C=O)- or H(C=O)N(OH)-; X represents -O- or -S-; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0204159.8A GB0204159D0 (en) | 2002-02-22 | 2002-02-22 | Metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU71604A true YU71604A (sh) | 2006-08-17 |
| RS51354B RS51354B (sr) | 2011-02-28 |
Family
ID=9931543
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US7358265B2 (sh) |
| EP (1) | EP1476438B1 (sh) |
| JP (1) | JP4615864B2 (sh) |
| KR (1) | KR101098614B1 (sh) |
| CN (1) | CN100351245C (sh) |
| AT (1) | ATE360007T1 (sh) |
| AU (1) | AU2003205910B2 (sh) |
| BR (1) | BR0307899A (sh) |
| CA (1) | CA2475867C (sh) |
| CY (1) | CY1106730T1 (sh) |
| DE (1) | DE60313292T2 (sh) |
| DK (1) | DK1476438T3 (sh) |
| EA (1) | EA007609B1 (sh) |
| ES (1) | ES2286404T3 (sh) |
| GB (1) | GB0204159D0 (sh) |
| HK (1) | HK1078583A1 (sh) |
| HR (1) | HRP20040725A2 (sh) |
| IL (1) | IL163413A (sh) |
| MX (1) | MXPA04008132A (sh) |
| NO (1) | NO330772B1 (sh) |
| PL (1) | PL210773B1 (sh) |
| PT (1) | PT1476438E (sh) |
| RS (1) | RS51354B (sh) |
| SI (1) | SI1476438T1 (sh) |
| UA (1) | UA78275C2 (sh) |
| WO (1) | WO2003070711A1 (sh) |
| ZA (1) | ZA200406755B (sh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101537A1 (en) * | 2003-05-17 | 2004-11-25 | British Biotech Pharmaceuticals Ltd | Metalloproteinase inhibitors |
| PT1660471E (pt) | 2003-08-23 | 2011-08-03 | Merck Serono Sa | Derivados de ácido hidroxâmico como inibidores de metaloproteinase |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| BRPI0516383A (pt) | 2004-12-21 | 2008-09-02 | Serono Lab | derivados cìclicos de sulfonil amino e o uso dos mesmos |
| US7868009B2 (en) | 2005-01-31 | 2011-01-11 | Merck Serono, S.A. | N-hydroxyamide derivatives and use thereof |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| WO2007025991A2 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
| US8153166B2 (en) * | 2006-06-08 | 2012-04-10 | Chih-Hsiung Lin | Composition for prophylaxis or treatment of urinary system infection and method thereof |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| US10781189B2 (en) | 2015-03-10 | 2020-09-22 | Aurigene Discovery Technologies Limited | 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators |
| CA2979161A1 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CN105384736B (zh) * | 2015-10-28 | 2018-11-02 | 南昌大学 | 一种ⅳ型胶原酶抑制剂及合成方法 |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| EA202090536A1 (ru) | 2017-10-11 | 2020-07-22 | Ориджен Дискавери Текнолоджис Лимитед | Кристаллические формы 3-замещенного 1,2,4-оксадиазола |
| CA3080098A1 (en) | 2017-11-03 | 2019-05-09 | Aurigene Discovery Technologies Limited | Dual inhibitors of tim-3 and pd-1 pathways |
| JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
| CN108530378B (zh) * | 2018-05-29 | 2021-09-14 | 济南大学 | 一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404046D0 (en) * | 1994-03-03 | 1994-04-20 | Smithkline Beecham Corp | Novel compounds |
| US5665753A (en) * | 1994-03-03 | 1997-09-09 | Smithkline Beecham Corporation | Cytokine inhibiting imidazole substituted hydroxamic acid derivatives |
| US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
| WO1998026773A1 (en) * | 1996-12-17 | 1998-06-25 | Warner-Lambert Company | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| EP1064289A1 (en) * | 1998-03-18 | 2001-01-03 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
| JP2001031637A (ja) * | 1999-05-17 | 2001-02-06 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体 |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| US6448278B2 (en) * | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
-
2002
- 2002-02-22 GB GBGB0204159.8A patent/GB0204159D0/en not_active Ceased
-
2003
- 2003-02-20 WO PCT/GB2003/000741 patent/WO2003070711A1/en active IP Right Grant
- 2003-02-20 EA EA200401095A patent/EA007609B1/ru not_active IP Right Cessation
- 2003-02-20 KR KR1020047012821A patent/KR101098614B1/ko not_active IP Right Cessation
- 2003-02-20 RS YUP-716/04A patent/RS51354B/sr unknown
- 2003-02-20 US US10/504,317 patent/US7358265B2/en not_active Expired - Fee Related
- 2003-02-20 PL PL372268A patent/PL210773B1/pl unknown
- 2003-02-20 ES ES03702791T patent/ES2286404T3/es not_active Expired - Lifetime
- 2003-02-20 EP EP03702791A patent/EP1476438B1/en not_active Expired - Lifetime
- 2003-02-20 SI SI200330870T patent/SI1476438T1/sl unknown
- 2003-02-20 JP JP2003569618A patent/JP4615864B2/ja not_active Expired - Fee Related
- 2003-02-20 AU AU2003205910A patent/AU2003205910B2/en not_active Ceased
- 2003-02-20 CN CNB038089122A patent/CN100351245C/zh not_active Expired - Fee Related
- 2003-02-20 AT AT03702791T patent/ATE360007T1/de active
- 2003-02-20 UA UA20040806941A patent/UA78275C2/uk unknown
- 2003-02-20 PT PT03702791T patent/PT1476438E/pt unknown
- 2003-02-20 CA CA2475867A patent/CA2475867C/en not_active Expired - Fee Related
- 2003-02-20 BR BR0307899-0A patent/BR0307899A/pt not_active IP Right Cessation
- 2003-02-20 MX MXPA04008132A patent/MXPA04008132A/es active IP Right Grant
- 2003-02-20 DK DK03702791T patent/DK1476438T3/da active
- 2003-02-20 DE DE60313292T patent/DE60313292T2/de not_active Expired - Lifetime
-
2004
- 2004-08-09 IL IL163413A patent/IL163413A/en not_active IP Right Cessation
- 2004-08-10 HR HR20040725A patent/HRP20040725A2/hr not_active Application Discontinuation
- 2004-08-25 ZA ZA200406755A patent/ZA200406755B/en unknown
- 2004-09-14 NO NO20043846A patent/NO330772B1/no not_active IP Right Cessation
-
2006
- 2006-01-26 HK HK06101230A patent/HK1078583A1/xx not_active IP Right Cessation
-
2007
- 2007-07-13 CY CY20071100937T patent/CY1106730T1/el unknown
-
2008
- 2008-02-08 US US12/028,275 patent/US20080227833A1/en not_active Abandoned
-
2009
- 2009-10-14 US US12/588,372 patent/US20100035943A1/en not_active Abandoned
-
2010
- 2010-10-07 US US12/900,262 patent/US20110086893A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU71604A (sh) | Oksa-i tijadijazoli i njihova upotreba kao inhibitora metalo proteinaze | |
| UY27972A1 (es) | Derivados de hidantoína | |
| MX2007005408A (es) | Compuestos de aminoquinazolinas. | |
| RS93604A (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| NO20042161L (no) | Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1 | |
| ATE363280T1 (de) | Verwendung von pioglitazone zur verbesserung der ketose und der azidose | |
| BR0312103A (pt) | Combinações de substâncias ativas fungicidas | |
| NO992492L (no) | Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer | |
| SE0301888D0 (sv) | New use VII | |
| NO20031482D0 (no) | Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer | |
| BR0211282A (pt) | Formulação farmacêutica | |
| NO20063944L (no) | Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister | |
| MXPA03006224A (es) | Inhibidores de cruzipaina y otras proteasas de cisteina. | |
| AU2001266575A1 (en) | Chemical compounds | |
| HK1096548A1 (en) | Imidazopyridine-derivatives as inductible no-synthase inhibitors | |
| NO20015892L (no) | Inhibitorer av metallproteinaser | |
| WO2004043349A3 (en) | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
| DK1558580T3 (da) | N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner | |
| SE0203302D0 (sv) | Novel Compounds | |
| RS20060206A (en) | Aminopyridine-derivatives as inducible no-synthase inhibitors | |
| BR0108500A (pt) | Arilpiperazinas e arilpiperidinas e seu uso como agentes inibidores de metaloproteinase | |
| ATE320422T1 (de) | Metalloproteinase inhibitoren | |
| PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
| TW200509921A (en) | Alkaline salts | |
| MXPA05000517A (es) | Derivados de sulfonilpiperidina que contienen una porcion alquenilo o alquinilo para uso como inhibidores de metaloproteinasas de matriz. |